European country orders 440k mpox vaccines

Bavarian Nordic, a Danish pharmaceutical company, has secured a contract to deliver 440,000 doses of mpox vaccines to an unidentified European country, with deliveries scheduled for 2024. This deal pushes the company’s public preparedness contracts close to 3 billion DKK in value. Following this order, Bavarian Nordic raises its financial forecast, anticipating revenues between 5,000 and 5,300 million DKK and an operating profit of 1,100 to 1,350 million DKK. The firm asserts its capacity to supply up to ten million doses of the smallpox and mpox vaccine by the end of next year. Recently, Bavarian Nordic also received an order for 175,000 doses for Africa. The company is currently working on approving the vaccine for children aged 12-17, with potential approval in the fourth quarter of 2024. Mpox, previously known as monkeypox, predominantly affects children under 15 and can spread through close contact but is generally mild and rarely fatal.